Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Follitropin delta - Ferring Pharmaceuticals

Next Previous
Drug Profile

Follitropin delta - Ferring Pharmaceuticals

Alternative Names: FE-999049; Recombinant follicle-stimulating hormone - Ferring Pharmaceuticals; Recombinant FSH - Ferring; Rekovelle

Latest Information Update: 08 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ferring Pharmaceuticals
  • Class Follicle stimulating hormones; Infertility therapies; Peptide fragments; Pituitary gonadotropins; Recombinant proteins
  • Mechanism of Action Ovarian follicle stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Female infertility
  • Preregistration Male infertility

Most Recent Events

  • 02 Jul 2025 Efficacy data from the phase II ADAPT-1 trial in Female infertility released by Ferring Pharmaceuticals
  • 31 May 2025 Ferring Pharmaceuticals completes the phase-III COCO trial in Female infertility in China (SC) (NCT06173869)
  • 23 Oct 2024 Ferring Pharmaceuticals terminates a phase II trial in Male infertility in USA, Denmark, Spain, Italy, Belgium, Germany, Sweden (SC) due to the probability of enroling patients in the trial in a reasonable timeframe being too low (NCT05403476)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top